Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Jun 2:10.1111/jdv.18246. Online ahead of print. doi: 10.1111/jdv.18246

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 European Academy of Dermatology and Venereology.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

(a) A photo was taken by the patient showing a multinodular tumour of the scalp. (b) Initial histological images: (b‐1) Cutaneous tissue in which the dermis is the site of a lymphomatous proliferation showing a diffuse growth pattern, extending into the hypodermis (HE ×10). (b‐2) Mixture of main centrocytes (large cleaved cells) and centroblasts, provided with irregular nuclei, with one or more prominent nucleoli, arranged within a fibrous stroma (HE ×40). Immunochemical images: (b‐3) Immunochemical labelling CD 20+. (b‐4) Immunochemical labelling Bcl6+. (b‐5) Immunochemical labelling CD10+. (b‐6) Immunochemical labelling Bcl2−. (c) Clinical image showing the disappearance of the scalp tumour after COVID‐19 vaccine, with a residual non‐infiltrated erythema. (d) Histological image after tumour regression showing fibrous scarring.